|
MechanismSGLT2 inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhaseClinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
|
MechanismDPP-4 inhibitors |
Active Org.- |
|
Active Indication- |
Inactive Indication- |
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Manipulation of L-Ascorbic Acid Level For The Treatment of Selected Cases Of Acute Myeloid Leukemia and Myelodysplastic Syndromes
To document therapeutic gain achieved by cyclic application of L-ascorbic acid (LAA) supplementation and depletion, while confirming safety and avoidance of clinically significant scurvy, in chemorefractory patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
100 Clinical Results associated with JIN YANG PHARMACEUTICAL Co., Ltd.
0 Patents (Medical) associated with JIN YANG PHARMACEUTICAL Co., Ltd.
100 Deals associated with JIN YANG PHARMACEUTICAL Co., Ltd.
100 Translational Medicine associated with JIN YANG PHARMACEUTICAL Co., Ltd.